LFB works for « the France of tomorrow » and unveils a new industrial project in Alès
LFB unveils today an investment project to increase its biomanufacturing capacities on its site in Alès (France). The aim of this project is to manufacture in Alès, from the 3rd quarter of 2021, commercial batches of the XENOTHERA biotech’s XAV-19 anti-COVID-19 drug candidate. LFB is thus pursuing its partnership announced in April 2020 with this French biotech, in order to manufacture clinical batches of this drug candidate to fight against COVID-19.
LFB is proud to be able to unveil this new industrial project, supported by the French State, which adds to the initiatives already undertaken with all its employees for over a year in the fight against the COVID-19 pandemic.